Dabur seeks USFDA for generic versions of Eloxatin

New Delhi, Jun 22 (UNI) Dabur Pharma Ltd today said the company and UK-based Dabur Oncology Pte have approached the US Food and Drug Administration (USFDA) seeking marketing approval for generic versions of Eloxatin.

Eloxatin which is marketed by Sanofi-Aventis, as an injectable, is used in treatement of bowel cancer.

The drug generated sales of 2.3 billion dollars. Generic versions of Eloxatin (Oxaliplatin) are available in several European Markets, the company said in a statement.

In response to the patent challenge, Sanofi-Aventis US LLC, Sanofi-Aventis and Debiopharm, SA have filed a lawsuit against Dabur Oncology Pte and the company.

The complaint alleges that the filing of the applications has infringed the already granted US Patents.

The Company and Dabur Oncology plc dispute the charges of infringement and intend to vigorously challenge these allegations.

UNI